These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
152 related articles for article (PubMed ID: 34721716)
1. Patient-Specific Dosimetry in Radioligand Therapy (RLT) for Metastatic Prostate Cancer Using Mahmoudi E; Pirayesh E; Deevband MR; Amoui M; Rad MG; Ghorbani M Nucl Med Mol Imaging; 2021 Oct; 55(5):237-244. PubMed ID: 34721716 [TBL] [Abstract][Full Text] [Related]
2. Dosimetry for (177)Lu-DKFZ-PSMA-617: a new radiopharmaceutical for the treatment of metastatic prostate cancer. Delker A; Fendler WP; Kratochwil C; Brunegraf A; Gosewisch A; Gildehaus FJ; Tritschler S; Stief CG; Kopka K; Haberkorn U; Bartenstein P; Böning G Eur J Nucl Med Mol Imaging; 2016 Jan; 43(1):42-51. PubMed ID: 26318602 [TBL] [Abstract][Full Text] [Related]
3. Lacrimal Glands May Represent Organs at Risk for Radionuclide Therapy of Prostate Cancer with [(177)Lu]DKFZ-PSMA-617. Hohberg M; Eschner W; Schmidt M; Dietlein M; Kobe C; Fischer T; Drzezga A; Wild M Mol Imaging Biol; 2016 Jun; 18(3):437-45. PubMed ID: 26920354 [TBL] [Abstract][Full Text] [Related]
4. Post-therapeutic dosimetry of 177Lu-DKFZ-PSMA-617 in the treatment of patients with metastatic castration-resistant prostate cancer. Yadav MP; Ballal S; Tripathi M; Damle NA; Sahoo RK; Seth A; Bal C Nucl Med Commun; 2017 Jan; 38(1):91-98. PubMed ID: 27782913 [TBL] [Abstract][Full Text] [Related]
5. Organ and tumor dosimetry including method simplification for [ Karimzadeh A; Schatz L; Sauer M; Apostolova I; Buchert R; Klutmann S; Lehnert W EJNMMI Phys; 2024 Jul; 11(1):63. PubMed ID: 39017988 [TBL] [Abstract][Full Text] [Related]
6. Comparison of Accuracy in Calculation of Absorbed Dose to the Kidneys Following Radioligand Therapy with Mahmoudi E; Pirayesh E; Deevband MR; Amoui M; Rad MG Indian J Nucl Med; 2022; 37(2):121-125. PubMed ID: 35982806 [TBL] [Abstract][Full Text] [Related]
7. Examining Absorbed Doses of Indigenously Developed Kamaldeep ; Wanage G; Sahu SK; Maletha P; Adnan A; Suman S; Basu S; Das T; Banerjee S Cancer Biother Radiopharm; 2021 Apr; 36(3):292-304. PubMed ID: 32379495 [No Abstract] [Full Text] [Related]
8. Personalized dosimetry assessment of [ Kazemi-Jahromi M; Yazdani E; Karamzade-Ziarati N; Asadi M; Sadeghi M; Geramifar P Int J Radiat Biol; 2024 Sep; ():1-9. PubMed ID: 39302840 [TBL] [Abstract][Full Text] [Related]
9. Pre-therapeutic dosimetry of normal organs and tissues of (177)Lu-PSMA-617 prostate-specific membrane antigen (PSMA) inhibitor in patients with castration-resistant prostate cancer. Kabasakal L; AbuQbeitah M; Aygün A; Yeyin N; Ocak M; Demirci E; Toklu T Eur J Nucl Med Mol Imaging; 2015 Dec; 42(13):1976-83. PubMed ID: 26227531 [TBL] [Abstract][Full Text] [Related]
10. Dosimetry and safety of Paganelli G; Sarnelli A; Severi S; Sansovini M; Belli ML; Monti M; Foca F; Celli M; Nicolini S; Tardelli E; Marini I; Matteucci F; Giganti M; Di Iorio V; De Giorgi U Eur J Nucl Med Mol Imaging; 2020 Dec; 47(13):3008-3017. PubMed ID: 32430583 [TBL] [Abstract][Full Text] [Related]